Table 4 Time-to-onset analysis for signals with PD-1/PD-L1.

From: Unraveling the mechanisms of irAEs in endometrial cancer immunotherapy: insights from FAERS and scRNA-seq data

Drugs

Cases (n)

TTO (days)

P

Weibull distribution

Failure type

Scale parameter

(95% two-sided CI)

Shape parameter

(95% two-sided CI)

 

PD-1

240

28 (12–79.25)

<0.0001

58.57 (47.46, 69.69)

0.71 (0.64, 0.77)

Early Failure

PD-L1

61

58 (22–132)

 

111.51 (71.00, 152.03)

0.73 (0.60, 0.87)

Early Failure

Back to article page